As technology continues to grow and change in huge ways, 2015 is looking to be the year for biotech companies. The research and development arena is seeing billions of dollars in investments come in for drug development, with every company wanting to be on the leading edge of new technologies. It seems as though the dollars are flooding the biotech market and leaving big pharma out to dry.
As with any industry, it’s smart to be cautious and not just jump into something because it’s the new “cool” thing to do. It’s definitely an exciting time to have an eye on such a growing industry, with the power to produce some products that could truly help people. The market can be tough to navigate; hopefully this quick list will help break it down.
Cannabis Science Inc. (OTCMKTS:CBIS)
Cannabis Science, Inc. develops, produces, and commercializes phytocannabinoid-based pharmaceutical products. It develops medicines to treat autism, blood pressure, cancer and cancer side effects, and other illnesses, including general health maintenance. The company is developing CS-TATI-1 for newly diagnosed and treatment-experienced patients with drug-resistant HIV strains; CS-S/BCC-1 for basal and squamous cell carcinomas; and a proprietary cannabis-based therapy for neurological conditions.
Cannabis Science, Inc. has been in the news lately with the announcement of the release of 8 cannabis based products that will be distributed in California, Spain and the Netherlands for self-medicating patient use for critical ailments and pre-clinical studies.
Oxis International, Inc. (OTCMKTS:OXIS)
OXIS International, Inc. (OXIS) is a biotech company that develops and commercializes innovative drugs of therapeutic molecules including cannabinoids, which are focused on several cancer indications. Oxis addresses the clinical shortcomings of existing commercial products in related fields. OXIS has formed relationships with some of the world’s leading cannabinoid researchers and institutions to advance its technologies.
Oxis Biotech is a subsidiary of Oxis International, Inc. Shortly after the first of the year they announced that they had secured exclusive patent licensing for a multiple myeloma therapy they are working on. With that announcement they also introduced Dr. Xiang-Qun Xie, a Professor of Pharmaceutical Sciences at the University of Pittsburg to head up the development f the multiple myeloma therapy. And most recently, they appointed the highly experienced Dr. James J Mulé to their Scientific Advisory Board.
Oxis has seen solid trading so far in 2015. Good volume along with a lot of attention lately surrounding any news the company releases made this one an obvious pick for the watch list.
Medical Marijuana, Inc. (OTCMKTS:MJNA)
Medical Marijuana, Inc. operates in the medical marijuana and industrial hemp markets. Its products range from patented and proprietary based cannabinoid products to seed and stalk or isolated high value extracts manufactured and formulated for the pharmaceutical, nutraceutical, and cosmeceutical industries. The company develops cannabinoid-based health and wellness products, and medical grade cannabinoid compounds; and licenses its proprietary testing, genetics, labeling and packaging, tracking, production, and standardization methods for the medicinal cannabinoid industry, as well as offers pre-and-post production tracking, gemplasm references, and packaging and processing services. Its products include Real Scientific Hemp Oil, Cibaderm, Cibdex, and Dixie Botanicals.
The company also engages in the management, capitalization, and development of health and wellness facilities, medical clinics, and cooperatives. In addition, it offers cannabidiol based products to consumers; chewing gum-based cannabis/cannabinoid medical products for the treatment of pain and other medical disorders; and cannabidiol hemp oil.
Medical Marijuana, Inc. started off 2015 with the recent acquisition of Kannaway, LLC, which is a network sales, and marketing company that specializes in the marketing of hemp-based botanical products.
Strong volume, and some good upward momentum lately has MJNA looking like a solid contender in 2015.
The biotech industry can be just as risky as any other industry out there. 2015 looks like it could be an interesting year, especially when it comes to medical cannabis and biotechs. With medical cannabis now legal in 23 US states, this opens up the way to more growth in the industry.
About marijuanastocks.com
MarijuanaStocks.com is the leading web destination for all things cannabis. Investors can find marijuana related financial, medical, legal, and social news anytime day or night. Writers are invited to submit cannabis related articles for publication.
Legal Disclaimer
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. DAMJ VENTURES LLC which owns www.MarijuanaStocks.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release.
DAMJ VENTURES LLC, which owns www.MarijuanaStocks.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. DAMJ VENTURES LLC, which owns www.MarijuanaStocks.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two.
Contact Information:
marijuanastocks.com
800-539-4313
pr@marijuanastocks.com